← All trials
NCT06284876
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2024
- Primary completion
- Aug 30, 2026
- Completion date
- Feb 28, 2027
- First posted
- Feb 29, 2024
- Last posted
- Feb 29, 2024
- Enrollment
- 416
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Il-Yang Pharm. Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.